Newron Pharmaceuticals S.p.A.
NP5
Rangering i aksjer
#17872
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Aksjekurs
$10.32
Markedsverdi
$211.01M
Endring (1 dag)
-2.25%
Endring (1 år)
-40.13%
Land
IT
Handel Newron Pharmaceuticals S.p.A. (NP5)
Kategori
Healthcare
Markedsverdi av Newron Pharmaceuticals S.p.A.(NP5)
Markedsverdi: $211.01M
Per October 2026 har Newron Pharmaceuticals S.p.A. en markedsverdi på $211.01M. Dette gjør Newron Pharmaceuticals S.p.A. til det 17872nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Newron Pharmaceuticals S.p.A. fra 2015 til 2026
NP5 sammenlignet med topp 5 mest populære stocks
